PRE 14A: Preliminary proxy statements relating to merger or acquisition
424B3: Prospectus
EFFECT: Others
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 4: Statement of changes in beneficial ownership of securities-Officer Audet Juliette Berangere
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 8-K: Current report
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 4: Statement of changes in beneficial ownership of securities-Director Topper James N
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 4: Statement of changes in beneficial ownership of securities-Officer Kastelein Johannes Jacob Pieter
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 144: Notice of proposed sale of securities pursuant to Rule 144
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 424B3: Prospectus
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | EFFECT: Others
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 8-K: Current report
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BCLS Fund III Investments, LP(6.0%),BCLS II Investco, LP(5.4%), etc.
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 8-K: Current report
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 10-K: Annual report
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 4: Statement of changes in beneficial ownership of securities-Director LANGE LOUIS G
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-James N. Topper(14.2%),Patrick J. Heron(14.2%), etc.
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 8-K: Current report
NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) | 424B5: Prospectus
No Data